MoonLake Immunotherapeutics Accounts Payable

As of the most recent data (June 2026), MLTX shows a accounts payable of $17M. That compares with $15M in the prior-year period — up 14.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MLTX's accounts payable is now $17M (was $15M) — a 14.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether MoonLake Immunotherapeutics is outperforming or lagging.

Tracking MLTX's accounts payable over time shows whether MoonLake Immunotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $17M That compares with $15M in the prior-year period — up 14.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has MoonLake Immunotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $17M) with ownership activity and broader fundamentals.